AbbVie stock (US00287Y1091): focus on Humira successors after latest quarterly update

AbbVie has reported new quarterly figures and updated guidance, while investors watch how fast newer immunology drugs can offset declining Humira sales. What drives the pharma heavyweight’s business model and why the stock remains in focus for US investors.

AbbVie reported its first-quarter 2026 results on 04/26/2026, highlighting continued growth from newer immunology and oncology drugs while legacy blockbuster Humira declined in the face of biosimilar competition, according to AbbVie press release as of 04/26/2026. The company confirmed its full-year adjusted earnings guidance and emphasized the contribution from Skyrizi and Rinvoq to offset revenue pressure.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AbbVie Inc.
• Sector/industry: Pharmaceuticals, biotechnology
• Headquarters/country: North Chicago, United States
• Core markets: Immunology, oncology, neuroscience, aesthetics
• Key revenue drivers: Prescription drugs such as Skyrizi, Rinvoq and oncology therapies
• Home exchange/listing venue: New York Stock Exchange (ticker: ABBV)
• Trading currency: US dollar (USD)

AbbVie: core business model

AbbVie operates as a large research-driven biopharmaceutical company that focuses on discovering, developing and commercializing medicines for serious chronic and acute conditions. The group was spun off from Abbott Laboratories in 2013 and has since built a broad portfolio across immunology, oncology, neuroscience and medical aesthetics, according to AbbVie company information as of 03/15/2026. A key part of the strategy is to pair internal R&D with targeted acquisitions and partnerships.

Historically, AbbVie relied heavily on Humira, an immunology drug indicated for conditions such as rheumatoid arthritis and Crohn’s disease. Humira generated tens of billions of dollars in annual sales before facing biosimilar competition in major markets, according to the company’s 2023 annual report published on 02/16/2024. To reduce this single-product dependence, management has spent years investing in successor products, especially Skyrizi and Rinvoq, as well as expanding into oncology and neuroscience.

Today, AbbVie’s business model combines high-margin specialty drugs with a global commercial footprint that reaches patients in more than 175 countries, as described in the firm’s corporate profile updated on 01/10/2026. The company’s revenue stream is largely driven by patented medicines, which typically allow premium pricing but are time limited due to patent expirations. This dynamic makes continuous innovation and lifecycle management essential for long-term growth.

In addition to prescription medicines, AbbVie also generates significant revenue from its aesthetics portfolio, which includes Botox Cosmetic and other products obtained through the acquisition of Allergan in 2020. These brands give AbbVie exposure not only to reimbursed healthcare markets but also to out-of-pocket consumer demand, offering a somewhat different sensitivity to economic cycles than traditional pharmaceuticals.

The company’s strategy places strong emphasis on late-stage clinical programs that can reach blockbuster scale. AbbVie typically guides investors on peak sales expectations for major pipeline candidates during its R&D and investor days, providing transparency on how it intends to replace expiring revenue streams. Management has frequently pointed to immunology and oncology as the most important long-term growth pillars, supported by a growing pipeline of biologics and targeted therapies.

Main revenue and product drivers for AbbVie

During the first quarter of 2026, AbbVie reported that global net revenues were broadly stable as growth from newer products offset the decline in Humira, according to AbbVie investor update as of 04/26/2026. Immunology remained the largest contributor, with Skyrizi and Rinvoq posting double-digit growth and continuing to gain market share in their respective indications. These two medicines form the backbone of AbbVie’s post-Humira strategy in immunology.

Skyrizi, a treatment for plaque psoriasis and other inflammatory conditions, has benefited from favorable clinical data and physician adoption. Rinvoq, an oral JAK inhibitor used in rheumatoid arthritis and several other immune-mediated diseases, has also expanded its label into additional indications over recent years. AbbVie has stated in earlier presentations that the combined peak sales potential of Skyrizi and Rinvoq is expected to exceed Humira’s peak levels, according to commentary in the company’s 2023 R&D day materials published on 12/07/2023.

Oncology is another major revenue driver. AbbVie markets Imbruvica in partnership with Johnson & Johnson, though intensifying competition in hematologic cancers has weighed on that franchise over time. To diversify, AbbVie has been investing in newer oncology agents, including Venclexta and a range of solid-tumor candidates in clinical development, as noted in the 2025 pipeline overview released on 01/22/2025. The aim is to build a sustainable oncology portfolio that can contribute meaningfully through the next decade.

Neuroscience and aesthetics also play important roles in AbbVie’s revenue mix. In neuroscience, products such as Botox Therapeutic and Vraylar address conditions including migraine and psychiatric disorders. In aesthetics, Botox Cosmetic and Juvederm provide exposure to elective procedures that are influenced by consumer confidence and disposable income trends. Management highlighted steady demand in aesthetics during the first-quarter 2026 update, even as it acknowledged that macroeconomic conditions can create fluctuations in procedure volumes over shorter periods.

Beyond individual brands, AbbVie’s revenue model depends on its ability to secure reimbursement and pricing across different healthcare systems worldwide. In the United States, which remains the company’s largest single market by sales, negotiations with pharmacy benefit managers and insurers influence net pricing and formulary positioning. Outside the US, centrally negotiated prices and reference pricing mechanisms play a bigger role, which can affect margins but also provide more predictable volume in some regions.

Why AbbVie matters for US investors

AbbVie is one of the largest constituents of major US equity indices such as the S&P 500, and its shares trade actively on the New York Stock Exchange under the ticker ABBV. Because of its considerable market capitalization and dividend payments, the stock often features prominently in US income and healthcare-focused portfolios, according to index composition data from the S&P Dow Jones Indices factsheet dated 03/31/2026. This means that AbbVie’s quarterly results and guidance can influence broader sentiment in the US healthcare sector.

The company has a track record of paying regular dividends and has emphasized shareholder returns through dividends and share repurchases over time, as outlined in its 2023 annual report published on 02/16/2024. For many US-based investors, healthcare stocks with consistent cash flows and dividend streams are seen as potential stabilizing elements in diversified portfolios, especially during periods of economic uncertainty. AbbVie’s cash generation from high-margin specialty drugs gives it financial flexibility to invest in R&D while also returning capital to shareholders.

US investors also watch AbbVie because its fortunes are closely tied to regulatory and pricing developments in the domestic market. Discussions around drug pricing reform, Medicare negotiations and biosimilar competition can have direct implications for the company’s revenue trajectory. AbbVie’s experience with the US launch of Humira biosimilars in 2023 is seen as a reference case for how large biopharmaceutical firms may navigate similar challenges with other aging blockbusters in the future.

In addition, AbbVie’s pipeline decisions and acquisition strategy can shape innovation trends in US biotech. When the company licenses or acquires promising experimental therapies from smaller biotech firms, it can provide funding and validation for early-stage science. Conversely, shifts in AbbVie’s appetite for deals can influence valuations across parts of the US biotech sector, particularly in areas such as immunology and oncology where the company is an active player, according to transaction analyses published by sector research firms in late 2025.

Conclusion

AbbVie is navigating a complex transition as it manages declining Humira revenues while scaling newer immunology, oncology, neuroscience and aesthetics assets. The first-quarter 2026 figures underlined that Skyrizi and Rinvoq remain central growth engines and that management is focused on sustaining overall earnings, according to the company’s update on 04/26/2026. For US investors, the stock reflects a blend of established cash flows, ongoing R&D risk and exposure to evolving drug pricing policies. How effectively AbbVie replenishes its portfolio and maintains competitive positions in key therapy areas is likely to remain a central factor in how the market assesses the company over the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.